KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Globus Medical (GMED) EBITDA Margin (2016 - 2026)

Globus Medical filings provide 15 years of EBITDA Margin readings, the most recent being 17.55% for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 1350.0% to 17.55% in Q4 2025 year-over-year; TTM through Dec 2025 was 19.06%, a 1484.0% increase, with the full-year FY2025 number at 19.06%, up 1484.0% from a year prior.
  • EBITDA Margin hit 17.55% in Q4 2025 for Globus Medical, up from 15.56% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 28.88% in Q2 2025 to a low of 1.31% in Q1 2024.
  • Median EBITDA Margin over the past 5 years was 15.76% (2022), compared with a mean of 13.05%.
  • Biggest five-year swings in EBITDA Margin: surged 2556bps in 2021 and later plummeted -2095bps in 2024.
  • Globus Medical's EBITDA Margin stood at 4.55% in 2021, then surged by 361bps to 21.01% in 2022, then crashed by -82bps to 3.82% in 2023, then grew by 6bps to 4.05% in 2024, then soared by 333bps to 17.55% in 2025.
  • The last three reported values for EBITDA Margin were 17.55% (Q4 2025), 15.56% (Q3 2025), and 28.88% (Q2 2025) per Business Quant data.